Skip to content
Screener

Other, net at other companies

Abbott logo
AbbottABT
-$20.5M
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$588M-1,570%
Stryker logo
StrykerSYK
-$147M-2,350%
Haemonetics logo
HaemoneticsHAE
-$14K+61.1%
CONMED logo
CONMEDCNMD
$182K-62.3%
Edwards Lifesciences logo
Edwards LifesciencesEW
$1.7M+143%

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$71.45B-53.2%
P/E19.5×-41.6×
P/S3.4×-4.8×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
(in millions)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from long-term borrowings, net of debt issuance costs1,558
Cash used to net share settle employee equity awards(85)(118)
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans81115
Other, net3(10)
Cash provided by (used for) financing activities(260)233
Effect of foreign exchange rates on cash(0)39
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents(504)314
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period2,147606

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's other, net?
Boston Scientific (BSX) reported other, net of $3M in Q1 2026.
How has Boston Scientific's other, net changed year-over-year?
Boston Scientific's other, net increased by 130.0% year-over-year, from -$10M to $3M.
What is the long-term trend for Boston Scientific's other, net?
Over 2 years (2023 to 2025), Boston Scientific's other, net has grown at a -69.8% compound annual growth rate (CAGR), from -$77M to $7M.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.

Ask your AI about Boston Scientific's other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude